Abstract
Increasing evidence points to the possible risks of delayed effects upon prenatal exposure to chemicals; the evaluation of such effects may pose serious problems to clinicians, epidemiologists and toxicologists. In fact, several systems (e.g., nervous, excretory) show important developmental processes well after the organogenetic period, up to the postnatal phase; accordingly, these are also expected to be sensitive targets of developmental toxicants, resulting in impairment of the function and/or functional reserve. This review describes the effects of several groups of drugs on the functional maturation and histogenesis of the kidney (e.g., aminoglycosides, angiotensin-converting enzyme inhibitors, indomethacin) and brain (e.g., anticonvulsivants, antiretroviral compounds, benzodiazepines) upon exposure in utero of humans and laboratory animals. The available data stress the importance for risk assessment of an adequate knowledge of both developmental biology and mechanisms of toxicity. The design of developmental toxicity studies should allow an evaluation of targets most relevant for a given drug (or group of drugs); moreover, the analysis of functional development should receive the due attention within the safety assessment of chemicals.
Keywords: aminoglycosides angiotensin-converting enzyme inhibitors, Aminoglycosides, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), dexamethasone, Glucocorticoids, Diuretic Agents, acetazolamide, amiloride, chlorothiazide
Current Pharmaceutical Design
Title: Delayed Developmental Effects Following Prenatal Exposure to Drugs
Volume: 7 Issue: 9
Author(s): Alberto Mantovani and Gemma Calamandrei
Affiliation:
Keywords: aminoglycosides angiotensin-converting enzyme inhibitors, Aminoglycosides, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), dexamethasone, Glucocorticoids, Diuretic Agents, acetazolamide, amiloride, chlorothiazide
Abstract: Increasing evidence points to the possible risks of delayed effects upon prenatal exposure to chemicals; the evaluation of such effects may pose serious problems to clinicians, epidemiologists and toxicologists. In fact, several systems (e.g., nervous, excretory) show important developmental processes well after the organogenetic period, up to the postnatal phase; accordingly, these are also expected to be sensitive targets of developmental toxicants, resulting in impairment of the function and/or functional reserve. This review describes the effects of several groups of drugs on the functional maturation and histogenesis of the kidney (e.g., aminoglycosides, angiotensin-converting enzyme inhibitors, indomethacin) and brain (e.g., anticonvulsivants, antiretroviral compounds, benzodiazepines) upon exposure in utero of humans and laboratory animals. The available data stress the importance for risk assessment of an adequate knowledge of both developmental biology and mechanisms of toxicity. The design of developmental toxicity studies should allow an evaluation of targets most relevant for a given drug (or group of drugs); moreover, the analysis of functional development should receive the due attention within the safety assessment of chemicals.
Export Options
About this article
Cite this article as:
Mantovani Alberto and Calamandrei Gemma, Delayed Developmental Effects Following Prenatal Exposure to Drugs, Current Pharmaceutical Design 2001; 7 (9) . https://dx.doi.org/10.2174/1381612013397717
DOI https://dx.doi.org/10.2174/1381612013397717 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Molecular Targets and Treatment of Idiopathic Pulmonary Fibrosis: Focus on TGFβ Signaling and the Myofibroblast
Current Medicinal Chemistry Biological Activities of Yarrow Species (Achillea spp.)
Current Pharmaceutical Design Rho as a Target to Promote Repair: Translation to Clinical Studies with Cethrin
Current Pharmaceutical Design Environmentally Benign Synthetic Protocol for the Synthesis of Spiroquinazolinones Using Sustainable and Recyclable Choline Chloride Based Deep Eutectic Mixture
Current Organic Synthesis Molecular Mechanisms of Complement System Proteins and Matrix Metalloproteinases in the Pathogenesis of Age-Related Macular Degeneration
Current Molecular Medicine Enhancement of Immunoprotective Effect of CpG-ODN by Formulation with Polyphosphazenes Against E. coli Septicemia in Neonatal Chickens
Current Drug Delivery Extracellular RNA, a Potential Drug Target for Alleviating Atherosclerosis, Ischemia/Reperfusion Injury and Organ Transplantation
Current Pharmaceutical Biotechnology Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Emerging Technologies in Biocompatible Surface Modifying Additives: Quest for Physiologic Cardiopulmonary Bypass
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Models in Research of Pharmacoresistant Epilepsy: Present and Future in Development of Antiepileptic Drugs
Current Medicinal Chemistry Synthesis and In Vitro Evaluation of Furan-Based Chalcone Derivatives as Antimicrobial Agents
Letters in Drug Design & Discovery Impact of Diabetes on Vasculature: Focus on Nervous System
Current Diabetes Reviews Recent Progress in Medicinal Investigations on Trichosanthin and other Ribosome Inactivating Proteins from the Plant Genus Trichosanthes
Current Medicinal Chemistry Candidiasis: A Fungal Infection- Current Challenges and Progress in Prevention and Treatment
Infectious Disorders - Drug Targets An Overview of Novel Coronavirus Disease 2019: A Global Havoc
Coronaviruses A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer's Disease
Current Pharmaceutical Design Is Going for Cure in CML Targeting Aberrant Glycogen Synthase Kinase 3β?
Current Drug Targets Fibronectin Expression in the Intervertebral Disc of Monkey
Current Stem Cell Research & Therapy Antibody-Targeted Immunoliposomes for Cancer Treatment
Mini-Reviews in Medicinal Chemistry Proteins of the Esterase Family: Patents for Some Proteins in Search of Metabolic Functions
Recent Patents on Biomarkers